Mara Capone
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mara Capone has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Claudia Patricia Tobar Cabrera
Department of Molecular Medicine, University of Pavia, 27100 Pavia, Italy
1 shared publication - Eleonora Gelli
Department of Molecular Medicine, University of Pavia, 27100 Pavia, Italy
1 shared publication - Elisa Roncoroni
Division of Hematology, Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy
1 shared publication - Gianluca Martini
Unit of Bone Marrow Transplantation and Cellular Therapies, Division of Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
1 shared publication - Giulia Gambini
Clinical Epidemiology and Biometry Service, Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy
1 shared publication - Luca Arcaini
Department of Molecular Medicine University of Pavia Pavia Italy
1 shared publication
Latest Publications
- Open Access
- 8 June 2023
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (6) , 1680
Pharmacokinetics of Venetoclax Co-Administered with Posaconazole in Patients with Acute Myeloid Leukemia
The Food and Drug Administration currently approves the combination of hypomethylating agents (HMA), azacytidine or decitabine with venetoclax (VEN) for acute myeloid leukemia (AML) patients aged more than 75 years and for patients unsuitable for intensive chemotherapy. The risk of fungal infection in the early phase of treatment is not negligible; therefore, posaconazole (PCZ) is commonly administered as primary prophylaxis. A drug–drug interaction between VEN and PCZ is well known, but the trend of serum levels of venetoclax when both drugs are overlapped is not clear. In total, 165 plasma samples from 11 elderly AML patients receiving combined treatment with HMA, VEN and PCZ were analyzed by a validated analytical method (high-pressure liquid chromatography–tandem mass spectrometry). Venetoclax trough plasma concentrations were detected during the 3 days of ramp-up as well as on day 7 and day 12 of treatment when the exposure as the area under the plasma concentration–time curve and the accumulation ratio were also calculated. The results were compared with the expected data for 400 mg/dose VEN administered alone—the confirmed high inter-individual variability in pharmacokinetics suggests the need for therapeutic drug monitoring.
- 8 June 2023
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (6) , 1680
Open AccessPharmacokinetics of Venetoclax Co-Administered with Posaconazole in Patients with Acute Myeloid Leukemia
The Food and Drug Administration currently approves the combination of hypomethylating agents (HMA), azacytidine or decitabine with venetoclax (VEN) for acute myeloid leukemia (AML) patients aged more than 75 years and for patients unsuitable for intensive chemotherapy. The risk of fungal infection in the early phase of treatment is not negligible; therefore, posaconazole (PCZ) is commonly administered as primary prophylaxis. A drug–drug interaction between VEN and PCZ is well known, but the trend of serum levels of venetoclax when both drugs are overlapped is not clear. In total, 165 plasma samples from 11 elderly AML patients receiving combined treatment with HMA, VEN and PCZ were analyzed by a validated analytical method (high-pressure liquid chromatography–tandem mass spectrometry). Venetoclax trough plasma concentrations were detected during the 3 days of ramp-up as well as on day 7 and day 12 of treatment when the exposure as the area under the plasma concentration–time curve and the accumulation ratio were also calculated. The results were compared with the expected data for 400 mg/dose VEN administered alone—the confirmed high inter-individual variability in pharmacokinetics suggests the need for therapeutic drug monitoring.